Business
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which underscored the importance of potential reproductive health options
About this update from Femasys Inc.
[{"type":"text","content":"- 2022 was a landmark year for women in the U.S. due to the overturn of Roe v. Wade which underscored the importance of potential reproductive health options like Femasys’ FemBloc® for permanent birth control and FemaSeed® for infertility - The commercial launches of FemCath™ and FemCerv® broaden options for women while Femasys continues advancing development of its lead clinical programs FemBloc and FemaSeed® ATLANTA, March 30, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the year ended December 31, 2022 and provided a corporate update. “This past year was a watershed moment for women in the United States with the overturn of the landmark Roe v. Wade case by the U.S. Supreme Court,” stated Kathy Lee-Sepsick, founder, president and chief executive officer. “The Court’s decision made us more determined than ever to bring our novel permanent birth control solution, FemBloc® and infertility solution, FemaSeed®, to women in the U.S. and around the world. The excitement about our FemBloc and FemaSeed programs was palpable during our recent participation in a panel at the South by Southwest conference where the impact of the Dobbs decision on reproductive health was discussed. With the recent challenges and unmet needs that are highly apparent in women’s health, we are both energized and inspired in the new year as we become closer to providing safe and affordable alternatives for women worldwide throughout the spectrum of reproduction.” 2022 and Recent Corporate Highlights Operational and Leadership In January 2022, Wendy Perrow joined as a new board member. Ms. Perrow brings decades of experience in the life sciences industry related to company-building, fundraising, corporate strategy, business and product development, regulatory, manufacturing and marketing in the life sciences. In February, Dov Elefant was appointed to chief financial officer (CFO). Mr. Elefant brings 25 years of financial management experience at both public and private biopharmaceutical companies. Mr. Elefant has a proven record as a senior level global financial expert with financial reporting, fundraising, and mergers and acquis...